Dr. Jeffrey Weber on the Keys to Targeted Treatments
November 7th 2015Jeffrey S. Weber, MD, PhD, deputy director, Laura and Isaac Perlmutter Cancer Center, co-director of its Melanoma Program, head of Experimental Therapeutics, NYU Langone Medical Center, discusses keys to targeted therapies for melanoma. These keys lie in BRAF and MEK inhibitors and combining those drugs with immunologic therapies.
Watch
Dr. Thomas Herzog on Who Benefits From Neoadjuvant Therapies
November 6th 2015Thomas Herzog, MD, clinical director, University of Cincinnati Cancer Institute, discusses the types of patients who benefit from neoadjuvant therapies. Patients who cannot undergo aggressive cytoreduction, patients with comorbidities and older patients would be ideal candidates to receive the therapy, he adds.
Watch
Dr. Maurie Markman on the Further Study of PD-1 Inhibitors in Ovarian Cancer
November 5th 2015Maurie Markman, MD, president of Medicine and Science, Eastern Regional Medical Center, talks about use of PD-1 inhibitors in ovarian cancer and the lack of evidence pointing toward their functionality.
Watch
Dr. Judy Boughey on the Safety of Nipple-Sparing Mastectomies
November 5th 2015Dr. Judy C. Boughey talks about a study examining all patients at Mayo Clinic that underwent a nipple-sparing mastectomy for breast cancer and comparing those with positive lymph nodes to those with negative lymph nodes.
Watch
Dr. Gregory Riely on Potential Treatment for Patients With MET Exon 14 Mutation
November 4th 2015Gregory J. Riely, MD, PhD, vice chair of the Clinical Trials Office in the Department of Medicine, Memorial Sloan Kettering Cancer Center, talks about non-small cell lung cancer (NSCLC) MET exon 14 mutations and their response to drugs like cabozantinib and crizotinib.
Watch
Dr. Pamela Kunz on the Effectiveness of Immunotherapies and Their Promising Future
November 3rd 2015Pamela Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, talks about the findings of the phase II study of everolimus plus bevacizumab in pNETs, as well as bevacizumab in progressive pNETS.
Watch
Dr. Lowell Anthony: Use of Telotristat Etiprate in Patients With Carcinoid Syndrome
October 31st 2015Lowell B. Anthony, MD, professor of Medicine, University of Kentucky, what community oncologists can take away from the phase III placebo-controlled TELESTAR trial, which evaluated telotristat etiprate in patients with inadequately controlled carcinoid syndrome.
Watch
Dr. Christiane Kuhl on the Overdiagnosis of Breast Cancer
October 30th 2015Christiane Kuhl, MD, Professor of Radiology and Vice Chairman of the Radiological department, Director of the Division of Oncologic Imaging and Interventional Therapy, Bonn University, talks about the over diagnosis of breast cancer through mammography screenings.
Watch
Dr. Hans-Christian Kolberg on Safer Chemotherapy for Patients with HER2-positive Early Breast Cancer
October 29th 2015Hans-Christian Kolberg, MD, doctor of Medicine, Marien Hospital Bottrop in Bottrop, Germany, discusses neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab for patients with HER2-positive early breast cancer.
Watch
Dr. Dirk Arnold on Sirflox and its Effect on Liver Metastases
October 28th 2015Dirk Arnold, MD, PhD, Professor and Head Dept. Hematology and Medical Oncology at Tumor Biology Center in Freiburg, Germany, talks about sirflox and its phase III trials on whether or not it can properly add local ablative treatment to diffuse metastasization of the liver.
Watch
Dr. Steven Gore on Potential Negative Effects of Further Research into Azanucleoside Combinations
October 28th 2015Steven D. Gore, MD, director of Hematologic Malignancies at Yale Cancer Center, talks about the risk of constantly testing azanucleoside combinations without significant results. Gore says that testing azanucleoside combinations that are not well planned may cause the medical community to overlook an effective combination due to fatigue of constant testing.
Watch
Dr. Clifford A. Hudis on Why Resistance to HER-2 Therapies Needs to be Further Researched
October 27th 2015Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, talks about the vague understanding medical professional currently have of HER-2 breast cancer and its resistance to certain therapies.
Watch